Literature DB >> 32753376

Immune Responses and Risk of Triple-negative Breast Cancer: Implications for Higher Rates among African American Women.

Joshua W Ogony1,2, Derek C Radisky2, Kathryn J Ruddy3, Steven Goodison1, Daniel P Wickland1, Kathleen M Egan4, Keith L Knutson5, Yan W Asmann1, Mark E Sherman6,2.   

Abstract

The etiology of triple-negative breast cancers (TNBC) is poorly understood. As many TNBCs develop prior to the initiation of breast cancer screening or at younger ages when the sensitivity of mammography is comparatively low, understanding the etiology of TNBCs is critical for discovering novel prevention approaches for these tumors. Furthermore, the higher incidence rate of estrogen receptor-negative breast cancers, and specifically, of TNBCs, among young African American women (AAW) versus white women is a source of racial disparities in breast cancer mortality. Whereas immune responses to TNBCs have received considerable attention in relation to prognosis and treatment, the concept that dysregulated immune responses may predispose to the development of TNBCs has received limited attention. We present evidence that dysregulated immune responses are critical in the pathogenesis of TNBCs, based on the molecular biology of the cancers and the mechanisms proposed to mediate TNBC risk factors. Furthermore, proposed risk factors for TNBC, especially childbearing without breastfeeding, high parity, and obesity, are more prevalent among AAW than white women. Limited data suggest genetic differences in immune responses by race, which favor a stronger Thr type 2 (Th2) immune response among AAW than white women. Th2 responses contribute to wound-healing processes, which are implicated in the pathogenesis of TNBCs. Accordingly, we review data on the link between immune responses and TNBC risk and consider whether the prevalence of risk factors that result in dysregulated immunity is higher among AAW than white women. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2020        PMID: 32753376      PMCID: PMC9576802          DOI: 10.1158/1940-6207.CAPR-19-0562

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  96 in total

1.  Ethnicity greatly influences cytokine gene polymorphism distribution.

Authors:  Steven C Hoffmann; Eran M Stanley; E Darrin Cox; Barbara S DiMercurio; Deloris E Koziol; David M Harlan; Allan D Kirk; Patrick J Blair
Journal:  Am J Transplant       Date:  2002-07       Impact factor: 8.086

2.  Alterations in the Immune Cell Composition in Premalignant Breast Tissue that Precede Breast Cancer Development.

Authors:  Amy C Degnim; Tanya L Hoskin; Muhammad Arshad; Marlene H Frost; Stacey J Winham; Rushin A Brahmbhatt; Alvaro Pena; Jodi M Carter; Melody L Stallings-Mann; Linda M Murphy; Erin E Miller; Lori A Denison; Celine M Vachon; Keith L Knutson; Derek C Radisky; Daniel W Visscher
Journal:  Clin Cancer Res       Date:  2017-01-26       Impact factor: 12.531

3.  Disparities in breast cancer subtypes among women in the lower Mississippi Delta Region states.

Authors:  Whitney E Zahnd; Recinda L Sherman; Hillary Klonoff-Cohen; Sara L McLafferty; Susan Farner; Karin A Rosenblatt
Journal:  Cancer Causes Control       Date:  2019-04-10       Impact factor: 2.506

Review 4.  Obesity and Triple-Negative Breast Cancer: Disparities, Controversies, and Biology.

Authors:  Eric C Dietze; Tanya A Chavez; Victoria L Seewaldt
Journal:  Am J Pathol       Date:  2017-11-09       Impact factor: 4.307

5.  Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs.

Authors:  Anna Diana; Elisena Franzese; Sara Centonze; Francesca Carlino; Carminia Maria Della Corte; Jole Ventriglia; Angelica Petrillo; Ferdinando De Vita; Roberto Alfano; Fortunato Ciardiello; Michele Orditura
Journal:  Curr Oncol Rep       Date:  2018-08-20       Impact factor: 5.075

6.  Cytokine SNPs: Comparison of allele frequencies by race and implications for future studies.

Authors:  Alison L Van Dyke; Michele L Cote; Angie S Wenzlaff; Susan Land; Ann G Schwartz
Journal:  Cytokine       Date:  2009-04-07       Impact factor: 3.861

Review 7.  Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.

Authors:  Giampaolo Bianchini; Justin M Balko; Ingrid A Mayer; Melinda E Sanders; Luca Gianni
Journal:  Nat Rev Clin Oncol       Date:  2016-05-17       Impact factor: 66.675

8.  Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8.

Authors:  Zachary C Hartman; Graham M Poage; Petra den Hollander; Anna Tsimelzon; Jamal Hill; Nattapon Panupinthu; Yun Zhang; Abhijit Mazumdar; Susan G Hilsenbeck; Gordon B Mills; Powel H Brown
Journal:  Cancer Res       Date:  2013-04-30       Impact factor: 12.701

9.  BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry.

Authors:  Tara M Friebel; Irene L Andrulis; Judith Balmaña; Amie M Blanco; Fergus J Couch; Mary B Daly; Susan M Domchek; Douglas F Easton; William D Foulkes; Patricia A Ganz; Judy Garber; Gord Glendon; Mark H Greene; Peter J Hulick; Claudine Isaacs; Rachel C Jankowitz; Beth Y Karlan; Judy Kirk; Ava Kwong; Annette Lee; Fabienne Lesueur; Karen H Lu; Katherine L Nathanson; Susan L Neuhausen; Kenneth Offit; Edenir I Palmero; Priyanka Sharma; Marc Tischkowitz; Amanda E Toland; Nadine Tung; Elizabeth J van Rensburg; Ana Vega; Jeffrey N Weitzel; Gemo Study Collaborators; Kent F Hoskins; Tara Maga; Michael T Parsons; Lesley McGuffog; Antonis C Antoniou; Georgia Chenevix-Trench; Dezheng Huo; Olufunmilayo I Olopade; Timothy R Rebbeck
Journal:  Hum Mutat       Date:  2019-07-03       Impact factor: 4.700

10.  Parity-related molecular signatures and breast cancer subtypes by estrogen receptor status.

Authors:  Melissa Rotunno; Xuezheng Sun; Jonine Figueroa; Mark E Sherman; Montserrat Garcia-Closas; Paul Meltzer; Tyisha Williams; Sallie Smith Schneider; D Joseph Jerry; Xiaohong R Yang; Melissa A Troester
Journal:  Breast Cancer Res       Date:  2014-07-08       Impact factor: 6.466

View more
  4 in total

1.  Towards defining morphologic parameters of normal parous and nulliparous breast tissues by artificial intelligence.

Authors:  Joshua Ogony; Thomas de Bel; Derek C Radisky; Jeroen van der Laak; Mark E Sherman; Jennifer Kachergus; E Aubrey Thompson; Amy C Degnim; Kathryn J Ruddy; Tracy Hilton; Melody Stallings-Mann; Celine Vachon; Tanya L Hoskin; Michael G Heckman; Robert A Vierkant; Launia J White; Raymond M Moore; Jodi Carter; Matthew Jensen; Laura Pacheco-Spann; Jill E Henry; Anna Maria Storniolo; Stacey J Winham
Journal:  Breast Cancer Res       Date:  2022-07-11       Impact factor: 8.408

2.  Experimental Study of Potential CD8+ Trivalent Synthetic Peptides for Liver Cancer Vaccine Development Using Sprague Dawley Rat Models.

Authors:  Sidra Zafar; Baogang Bai; Jinlei Guo; Syed Aun Muhammad; Syeda Tahira Qousain Naqvi; Muhammad Nauman Shabbir; Imran Imran; Rehan Sadiq Shaikh; Amjad Ali
Journal:  Biomed Res Int       Date:  2022-05-31       Impact factor: 3.246

3.  A Pooled Case-only Analysis of Reproductive Risk Factors and Breast Cancer Subtype Among Black Women in the Southeastern United States.

Authors:  Maureen Sanderson; Tuya Pal; Alicia Beeghly-Fadiel; Mary Kay Fadden; Steffie-Ann Dujon; Chrystina Clinton; Cecilia Jimenez; Jennifer Davis; Mieke Fortune; Jasmine Thompson; Kiera Benson; Nicholas Conley; Sonya Reid; Ann Tezak; Xiao-Ou Shu; Wei Zheng; William J Blot; Loren Lipworth
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-05-04       Impact factor: 4.254

4.  Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case-control study.

Authors:  Vesal Yaghoobi; Myrto Moutafi; Thazin Nwe Aung; Vasiliki Pelekanou; Sanam Yaghoubi; Kim Blenman; Eiman Ibrahim; Ioannis A Vathiotis; Saba Shafi; Anup Sharma; Tess O'Meara; Aileen I Fernandez; Lajos Pusztai; David L Rimm
Journal:  Breast Cancer Res       Date:  2021-12-14       Impact factor: 6.466

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.